44 related articles for article (PubMed ID: 7483805)
21. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.
Hanke T; Samuel RV; Blanchard TJ; Neumann VC; Allen TM; Boyson JE; Sharpe SA; Cook N; Smith GL; Watkins DI; Cranage MP; McMichael AJ
J Virol; 1999 Sep; 73(9):7524-32. PubMed ID: 10438842
[TBL] [Abstract][Full Text] [Related]
22. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells.
Sedlik C; Saron M; Sarraseca J; Casal I; Leclerc C
Proc Natl Acad Sci U S A; 1997 Jul; 94(14):7503-8. PubMed ID: 9207121
[TBL] [Abstract][Full Text] [Related]
23. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization.
Weber J; Fenyö EM; Beddows S; Kaleebu P; Björndal A
J Virol; 1996 Nov; 70(11):7827-32. PubMed ID: 8892904
[TBL] [Abstract][Full Text] [Related]
24. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
Martin SJ; Vyakarnam A; Cheingsong-Popov R; Callow D; Jones KL; Senior JM; Adams SE; Kingsman AJ; Matear P; Gotch FM
AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
26. Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals.
Klein MR; Veenstra J; Holwerda AM; Roos MT; Gow I; Patou G; Coutinho RA; De Wolf F; Miedema F
AIDS Res Hum Retroviruses; 1997 Mar; 13(5):393-9. PubMed ID: 9075480
[TBL] [Abstract][Full Text] [Related]
27. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.
Peters BS; Cheingsong-Popov R; Callow D; Foxall R; Patou G; Hodgkin K; Weber JN
J Infect; 1997 Nov; 35(3):231-5. PubMed ID: 9459393
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression.
Lindenburg CE; Stolte I; Langendam MW; Miedema F; Williams IG; Colebunders R; Weber JN; Fisher M; Coutinho RA
Vaccine; 2002 May; 20(17-18):2343-7. PubMed ID: 12009290
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers.
Weber J; Cheinsong-Popov R; Callow D; Adams S; Patou G; Hodgkin K; Martin S; Gotch F; Kingsman A
Vaccine; 1995 Jun; 13(9):831-4. PubMed ID: 7483805
[TBL] [Abstract][Full Text] [Related]
30. Development of a DNA-MVA/HIVA vaccine for Kenya.
Hanke T; McMichael AJ; Mwau M; Wee EG; Ceberej I; Patel S; Sutton J; Tomlinson M; Samuel RV
Vaccine; 2002 May; 20(15):1995-8. PubMed ID: 11983261
[TBL] [Abstract][Full Text] [Related]
31. Expression of human immunodeficiency virus antigens in an attenuated Salmonella typhi vector vaccine.
Hone DM; Lewis GK; Beier M; Harris A; McDaniels T; Fouts TR
Dev Biol Stand; 1994; 82():159-62. PubMed ID: 7958470
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis of HIV-1 infection by detection of antibody IgG to HIV-1 in urine with ultrasensitive enzyme immunoassay (immune complex transfer enzyme immunoassay) using recombinant proteins as antigens.
Hashida S; Hashinaka K; Saitoh A; Takamizawa A; Shinagawa H; Oka S; Shimada K; Hirota K; Kohno T; Ishikawa S
J Clin Lab Anal; 1994; 8(4):237-46. PubMed ID: 7523637
[TBL] [Abstract][Full Text] [Related]
33. Hybrid Ty virus-like particles.
Adams SE; Burns NR; Layton GT; Kingsman AJ
Int Rev Immunol; 1994; 11(2):133-41. PubMed ID: 8046274
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
